Prediabetes Market (By Drug Class: Diguanide, Thiazolidinediones; By Age Group: Children, Adult) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global prediabetes market was estimated at USD 201.65 million in 2023 and it is expected to surpass around USD 405.66 million by 2033, poised to grow at a CAGR of 7.24% from 2024 to 2033.

Key Pointers

• North America dominated the market with the largest market share of 42% in 2023.
• Asia Pacific region is expected to expand at the highest CAGR during the forecast period.
• By Age group, the adult segment (aged 18-49) held the largest revenue share of 49% in 2023.
• By Age group, the elderly segment is anticipated to grow at the noteworthy CAGR from 2024 to 2033.
• By Drug Class, the diguanides segment generated the maximum market share of 84% in 2023.
• By Drug Class, the SGLT2 inhibitors segment is expected to grow at the fastest CAGR between 2024 to 2033.

Prediabetes Market Overview

Prediabetes represents a critical healthcare challenge worldwide, characterized by elevated blood sugar levels that are not yet within the diabetic range. With its prevalence on the rise, the prediabetes market has garnered significant attention from healthcare professionals, researchers, and pharmaceutical companies alike.

The market landscape encompasses a diverse array of diagnostic tools, treatment options, and preventative measures aimed at managing and mitigating the progression of prediabetes to full-blown diabetes. From lifestyle interventions such as dietary modifications and increased physical activity to pharmacological interventions including metformin and other medications, there exists a spectrum of approaches to address this burgeoning health concern.

Prediabetes Market Growth Factors

The growth of the prediabetes market is propelled by an escalating prevalence of prediabetes worldwide, driven by sedentary lifestyles, unhealthy dietary habits, and rising obesity rates, underscores the urgent need for effective interventions. Additionally, increasing awareness among healthcare professionals and the general population about the risks associated with prediabetes and its progression to diabetes has spurred demand for diagnostic tools and preventative measures. Furthermore, advancements in medical technology and research, leading to the development of innovative diagnostic tests, personalized treatment options, and novel therapeutics, are driving market growth. Moreover, supportive government initiatives aimed at promoting early detection and management of prediabetes, coupled with reimbursement policies for diagnostic tests and interventions, are contributing to market expansion.

Prediabetes Market Trends:

• Rising Prevalence: The prediabetes market is witnessing a surge in prevalence globally, driven by lifestyle factors such as sedentary behavior, poor dietary choices, and increasing obesity rates.
• Focus on Early Detection: There's a growing emphasis on early detection of prediabetes through screening programs and diagnostic tests, enabling healthcare providers to intervene early and prevent progression to diabetes.
• Personalized Interventions: With advancements in medical technology and research, there's a shift towards personalized interventions for prediabetes management, including tailored lifestyle modifications and targeted pharmacotherapy.
• Digital Health Solutions: The integration of digital health solutions such as mobile apps, wearable devices, and telemedicine platforms is gaining traction in prediabetes management, offering convenient monitoring and support for individuals at risk.
• Lifestyle Modification Programs: Healthcare providers are increasingly prescribing structured lifestyle modification programs encompassing dietary counseling, exercise regimens, and behavioral therapy to empower individuals with prediabetes to make sustainable lifestyle changes.
• Pharmacological Innovations: Pharmaceutical companies are investing in the development of novel therapeutics for prediabetes, including glucose-lowering agents with improved efficacy and safety profiles, as well as drugs targeting underlying metabolic pathways.

Prediabetes Market Challenges:

• Stigma and Misconceptions: Stigma surrounding diabetes and misconceptions about prediabetes being a less serious condition hinder individuals from seeking timely medical attention and adopting preventive measures.
• Barriers to Screening: Access barriers, including lack of healthcare infrastructure, limited resources, and financial constraints, impede widespread screening initiatives for identifying individuals at risk of prediabetes.
• Complexity of Diagnosis: Prediabetes diagnosis relies on laboratory tests such as fasting plasma glucose, oral glucose tolerance test, and HbA1c, which may not always be readily available or accessible, leading to diagnostic challenges.
• Patient Adherence to Lifestyle Changes: Encouraging and sustaining behavior modifications, including dietary changes, regular exercise, and weight management, poses a challenge due to lifestyle factors, cultural norms, and socioeconomic influences.
• Treatment Compliance: Ensuring patient adherence to prescribed medications, particularly for long-term pharmacotherapy such as metformin, presents challenges related to side effects, perceived efficacy, and patient education.

Age Group Insights

In 2023, the adult segment (aged 18-49) dominated the market, commanding the largest revenue share at 49%. This age group, encompassing individuals between 18 and 49 years old, exhibits the highest prevalence of prediabetes. For instance, as per 2021 estimates from the CDC, approximately 38% of all U.S. adults fall into this category. The substantial prevalence of prediabetes in this demographic, compounded by the adoption of unhealthy lifestyles, fuels the growth of this segment.

Meanwhile, the elderly segment is poised to experience significant growth with a promising compound annual growth rate (CAGR) during the forecast period. Defined as individuals aged 50 and above, this demographic is particularly susceptible to developing prediabetes due to age-related metabolic changes. According to CDC data, an estimated 27.2 million people aged 65 and older in the U.S. have prediabetes as of 2021. The expanding global elderly population, coupled with the increasing availability of medication options for prediabetes treatment, is expected to propel the growth of this segment.

Drug Class Insights

In 2023, the diguanides segment emerged as the market leader, capturing the largest revenue share at 84%. Diguanides, which include metformin, constitute a prominent drug class utilized in the management of prediabetes and type 2 diabetes. Metformin, in particular, stands out as the most prescribed diguanide for prediabetes treatment. As of August 2023, it holds the distinction of being the sole medication recommended by the American Diabetes Association (ADA) for managing prediabetes in both adult and pediatric patients aged 10 and above, according to the National Center for Biotechnology Information (NCBI). The identification of individuals with prediabetes often involves considering a glycated hemoglobin A1C test range of 5.7-6.4% (39-47 mmol/mol) as reasonable, as outlined in the Standards of Medical Care in Diabetes 2022.

Concurrently, the SGLT2 inhibitors segment is poised for significant growth, anticipated to achieve a lucrative compound annual growth rate (CAGR) during the forecast period. SGLT2 inhibitors have garnered increasing attention for prediabetes treatment in recent years. This class of drugs functions by inhibiting the reabsorption of sugar from urine, resulting in glucose excretion and decreased blood sugar levels. Notable drugs in this category include dapagliflozin, sotagliflozin, canagliflozin, empagliflozin, and ertugliflozin. The comparatively favorable side effect profile and high efficacy of SGLT2 inhibitors contribute to their role in driving market growth

Regional Insights

In 2023, the North America region emerged as the market leader, commanding a revenue share of 42%. The region's dominance is attributed to several factors, including heightened awareness regarding the significance of early detection and intervention for prediabetes. With increasing prevalence rates, the market experiences expansion driven by initiatives aimed at addressing prediabetes risk factors. For instance, data from the American Diabetes Association (ADA) in 2021 revealed that 97.6 million adults aged 18 and above in the U.S. were diagnosed with prediabetes.

Meanwhile, the Asia Pacific region is poised for rapid growth, expected to achieve the fastest compound annual growth rate (CAGR) during the forecast period. This growth can be attributed to several factors, including increasing urbanization and the adoption of sedentary lifestyles, which contribute to the rising prevalence of prediabetes. Additionally, genetic predisposition and dietary habits, such as high consumption of sugary and processed foods, play a significant role in predisposing individuals to prediabetes in the region. Moreover, aging populations and shifting demographics further contribute to the escalating burden of prediabetes across Asia Pacific.

Prediabetes Market Key Companies

• Novo Nordisk
• Valbiotis
• RESVERLOGIX
• Caelus Health
• SciMar
• Boston Therapeutics
• Aphaia Pharma
• AstraZeneca
• Bristol-Myers Squibb

Recent Developments

• In November 2023, VALBIOTIS SA reported the successful outcomes of its product TOTUM•63 in a clinical study investigating its mode of action for treating prediabetes.
• April 2023 saw Aphaia Pharma initiating Phase 2 trials for its drug candidate APH-012, specifically designed for addressing prediabetes.
• January 2024 marked the launch of Wegovy by Novo Nordisk in the U.K. This GLP-1 analogue is now available for prescription to individuals with prediabetes as well as for weight management purposes.

Prediabetes Market Segmentations:

By Drug Class

• Diguanide
• Thiazolidinediones
• Glucagon-like Peptide-1 Agonists (GLP-1)
• SGLT2 Inhibitors
• DPP-4 Inhibitors
• Others

By Age group

• Children (12-18 years)
• Adults (18-49)
• Elderly (50+)

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa